oral hexavalent reassortant live attenuated rotavirus vaccine

The oral hexavalent reassortant live attenuated rotavirus vaccine is a multivalent biologic candidate designed for the prevention of acute gastroenteritis caused by rotavirus infection in infants. It utilizes a human-bovine reassortant platform, incorporating six distinct serotypes—typically G1, G2, G3, G4, G9, and P[8]—to provide broad protection against the most prevalent rotavirus strains globally and within China. The vaccine is manufactured using Vero cell culture technology and is administered orally. It is currently in Phase 3 clinical development, with trials focusing on batch consistency, immunogenicity, and safety in infants aged 6 to 12 weeks. The development is primarily led by the Wuhan Institute of Biological Products (WIBP), a subsidiary of Sinopharm, often in collaboration with regional centers such as the Hebei Provincial Center for Disease Prevention and Control for clinical evaluation.

Other names

Hexavalent rotavirus vaccine6-valent rotavirus vaccineoral hexavalent reassortant live attenuated rotavirus vaccine (Vero cell)